ATE311386T1 - Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit - Google Patents

Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit

Info

Publication number
ATE311386T1
ATE311386T1 AT02780364T AT02780364T ATE311386T1 AT E311386 T1 ATE311386 T1 AT E311386T1 AT 02780364 T AT02780364 T AT 02780364T AT 02780364 T AT02780364 T AT 02780364T AT E311386 T1 ATE311386 T1 AT E311386T1
Authority
AT
Austria
Prior art keywords
obesity
tetrahydropyrrolo
derivatives
producing
treatment
Prior art date
Application number
AT02780364T
Other languages
English (en)
Inventor
Roger A Smith
Wai C Wong
Stephen J O'connor
Soongyu Choi
Harold C E Kluender
Zhonghua Zhang
Rico C Lavoie
Jianmei Fan
Brent L Podlogar
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE311386T1 publication Critical patent/ATE311386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT02780364T 2001-09-24 2002-09-24 Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit ATE311386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32444301P 2001-09-24 2001-09-24
PCT/US2002/030541 WO2003027114A1 (en) 2001-09-24 2002-09-24 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity

Publications (1)

Publication Number Publication Date
ATE311386T1 true ATE311386T1 (de) 2005-12-15

Family

ID=23263607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02780364T ATE311386T1 (de) 2001-09-24 2002-09-24 Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit

Country Status (9)

Country Link
US (2) US7071207B2 (de)
EP (1) EP1432708B1 (de)
JP (1) JP2005504100A (de)
AT (1) ATE311386T1 (de)
CA (1) CA2461142A1 (de)
DE (1) DE60207744T2 (de)
ES (1) ES2252524T3 (de)
MX (1) MXPA04002249A (de)
WO (1) WO2003027114A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
CA2494091C (en) 2002-08-02 2011-02-01 Richard B. Toupence Substituted furo [2,3-b| pyridine derivatives
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
RU2339618C2 (ru) 2003-01-02 2008-11-27 Ф.Хоффманн-Ля Рош Аг Новые обратные агонисты рецептора св1
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
EP1660475B1 (de) * 2003-08-08 2008-05-28 Pfizer Italia S.r.l. Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
CA2613678A1 (en) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
CN101007815B (zh) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 吡咯并六元杂环化合物及其在医药上的用途
BRPI0707312B1 (pt) 2006-01-27 2022-06-07 Shanghai Hengrui Pharmacetical Co., Ltd Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
US8293762B2 (en) 2007-02-27 2012-10-23 Nerviano Medical Sciences S.R.L. Isoquinolinopyrrolopyridinones active as kinase inhibitors
AR066207A1 (es) * 2007-04-03 2009-08-05 Astrazeneca Ab Agentes terapeuticos 684
AR065909A1 (es) * 2007-04-03 2009-07-08 Astrazeneca Ab Agentes terapeuticos 685
WO2008134354A1 (en) * 2007-04-27 2008-11-06 Array Biopharma, Inc. TNF-α PRODUCTION INHIBITOR
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2003129B1 (de) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
EP2538784B1 (de) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazolderivate als antidiabetika
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
AR097325A1 (es) * 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1484140A (en) 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US4897390A (en) * 1987-07-21 1990-01-30 Ruhe Rodney C Novel anti-obesity compounds and method of use
CA2174543A1 (en) * 1993-10-20 1995-04-27 Nobuyuki Yasuda Indole derivative
KR100251522B1 (ko) * 1997-08-13 2000-08-01 김충섭 할로알콕시기를 함유하는 피롤[3,2-c]퀴놀린 유도체 및 약학적으로 허용되는 그의 염
ATE328887T1 (de) 1999-01-19 2006-06-15 Neurosearch As Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE447947T1 (de) * 1999-07-06 2009-11-15 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz

Also Published As

Publication number Publication date
DE60207744T2 (de) 2006-08-03
US20040224970A1 (en) 2004-11-11
EP1432708A1 (de) 2004-06-30
MXPA04002249A (es) 2004-06-29
US20060122215A1 (en) 2006-06-08
EP1432708B1 (de) 2005-11-30
DE60207744D1 (de) 2006-01-05
CA2461142A1 (en) 2003-04-03
JP2005504100A (ja) 2005-02-10
ES2252524T3 (es) 2006-05-16
WO2003027114A1 (en) 2003-04-03
US7071207B2 (en) 2006-07-04

Similar Documents

Publication Publication Date Title
ATE311386T1 (de) Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
MXPA04002037A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
TW200504034A (en) Therapeutic agents
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
TW200635903A (en) Therapeutic agents
MY129328A (en) Triamide-substituted heterobicyclic compounds
NO20063787L (no) Terapeutiske preparater
MXPA05013711A (es) Derivados 3-sustituidos de 5,6-diaril-pirazin-2-carboxi-amida y -2-sulfonamida, como moduladores de cb1.
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
TW200633986A (en) Therapeutic agents
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
IS6865A (is) Setnar alkýlamínafleiður og aðferðir við notkun þeirra
MXPA05003273A (es) Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos.
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
TW200509933A (en) Therapeutic agents
DK1747220T3 (da) Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE59909607D1 (de) Tan-1057 derivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties